Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Clinical trial NCT03007732 · COMPLETED

Trial details

NCT number: NCT03007732
Sponsor: David Oh
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Prostatic Neoplasms

Start date: 2017-05-17
Primary completion: 2025-03-31
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.